↓ Skip to main content

Residual macrovascular risk in 2013: what have we learned?

Overview of attention for article published in Cardiovascular Diabetology, January 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)

Mentioned by

1 news outlet
6 tweeters


142 Dimensions

Readers on

111 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Residual macrovascular risk in 2013: what have we learned?
Published in
Cardiovascular Diabetology, January 2014
DOI 10.1186/1475-2840-13-26
Pubmed ID

Jean-Charles Fruchart, Jean Davignon, Michel P Hermans, Khalid Al-Rubeaan, Pierre Amarenco, Gerd Assmann, Philip Barter, John Betteridge, Eric Bruckert, Ada Cuevas, Michel Farnier, Ele Ferrannini, Paola Fioretto, Jacques Genest, Henry N Ginsberg, Antonio M Gotto, Dayi Hu, Takashi Kadowaki, Tatsuhiko Kodama, Michel Krempf, Yuji Matsuzawa, Jesús Millán Núñez-Cortés, Carlos Calvo Monfil, Hisao Ogawa, Jorge Plutzky, Daniel J Rader, Shaukat Sadikot, Raul D Santos, Evgeny Shlyakhto, Piyamitr Sritara, Rody Sy, Alan Tall, Chee Eng Tan, Lale Tokgözoğlu, Peter P Toth, Paul Valensi, Christoph Wanner, Alberto Zambon, Junren Zhu, Paul Zimmet


Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of obesity, metabolic syndrome and type 2 diabetes. While best standards of care, including high-dose statins, can ameliorate the risk of vascular complications, patients remain at high risk of cardiovascular events. The Residual Risk Reduction Initiative (R3i) has previously highlighted atherogenic dyslipidaemia, defined as the imbalance between proatherogenic triglyceride-rich apolipoprotein B-containing-lipoproteins and antiatherogenic apolipoprotein A-I-lipoproteins (as in high-density lipoprotein, HDL), as an important modifiable contributor to lipid-related residual cardiovascular risk, especially in insulin-resistant conditions. As part of its mission to improve awareness and clinical management of atherogenic dyslipidaemia, the R3i has identified three key priorities for action: i) to improve recognition of atherogenic dyslipidaemia in patients at high cardiometabolic risk with or without diabetes; ii) to improve implementation and adherence to guideline-based therapies; and iii) to improve therapeutic strategies for managing atherogenic dyslipidaemia. The R3i believes that monitoring of non-HDL cholesterol provides a simple, practical tool for treatment decisions regarding the management of lipid-related residual cardiovascular risk. Addition of a fibrate, niacin (North and South America), omega-3 fatty acids or ezetimibe are all options for combination with a statin to further reduce non-HDL cholesterol, although lacking in hard evidence for cardiovascular outcome benefits. Several emerging treatments may offer promise. These include the next generation peroxisome proliferator-activated receptorα agonists, cholesteryl ester transfer protein inhibitors and monoclonal antibody therapy targeting proprotein convertase subtilisin/kexin type 9. However, long-term outcomes and safety data are clearly needed. In conclusion, the R3i believes that ongoing trials with these novel treatments may help to define the optimal management of atherogenic dyslipidaemia to reduce the clinical and socioeconomic burden of residual cardiovascular risk.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Mexico 2 2%
Netherlands 1 <1%
Canada 1 <1%
South Africa 1 <1%
Unknown 106 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 20 18%
Student > Ph. D. Student 15 14%
Student > Postgraduate 13 12%
Student > Master 12 11%
Professor > Associate Professor 7 6%
Other 29 26%
Unknown 15 14%
Readers by discipline Count As %
Medicine and Dentistry 50 45%
Biochemistry, Genetics and Molecular Biology 8 7%
Agricultural and Biological Sciences 7 6%
Nursing and Health Professions 4 4%
Social Sciences 4 4%
Other 15 14%
Unknown 23 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 December 2019.
All research outputs
of 17,361,274 outputs
Outputs from Cardiovascular Diabetology
of 1,002 outputs
Outputs of similar age
of 198,518 outputs
Outputs of similar age from Cardiovascular Diabetology
of 1 outputs
Altmetric has tracked 17,361,274 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,002 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,518 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them